Table 1 Subject characteristics.
CD n = 65 | UC n = 107 | IBS n = 18 | HS n = 20 | |
|---|---|---|---|---|
Age | ||||
Mean (range) | 36.32 [18–76] | 45.20 [18–80] | 39.0 [21–71] | 40.6 [19–68] |
Sex | ||||
Males (%) | 36 [55.4] | 62 [57.9] | 13 [72.2] | 12 [60] |
Females (%) | 29 [44.6] | 45 [42.1] | 5 [27.8] | 8 [40] |
Smoking | ||||
Current (%) | 19 [29] | 9 [8] | 2 [11] | 1 [5] |
Former (%) | 17 [26] | 48 [45] | 3 [17] | 5 [25] |
Never (%) | 28 [43] | 50 [47] | 13 [72] | 14 [70] |
BMI | 25 [16–51] | 26 [17–56] | 24 [19–37] | 26 [19–44] |
Disease duration | 6.7 [0–38] | 8.3 [0.1–39] | ||
Treatmenta | ||||
5-ASA, topical | 0 [0] | 30 [28] | ||
5-ASA, oral | 7 [11] | 71 [66] | ||
Corticosteroids, topical | 0 [0] | 2 [2] | ||
Corticosteroids, oral | 4 [6] | 7 [6] | ||
Corticosteroid, iv | 2 [3] | 3 [3] | ||
Immunosuppressant | 23 [35] | 18 [17] | ||
Biologic agents | 39 [60] | 22 [21] | ||
No treatment | 6 [9] | 12 [11] | ||
Clinical disease activity | ||||
HBI (remission/mild/moderate/severe) (n = 65) | 41/13/10/1 | |||
Mayo partial (remission/mild/moderate/severe) (n = 107) | 52/23/28/4 | |||
Endoscopic disease activity | ||||
SES-CD (remission/mild/moderate/severe) (n = 17) | 7/3/5/2 | |||
Mayo endo (remission/mild/moderate/severe) (n = 63) | 11/21/20/11 | |||
Montreal classification CD | ||||
Age at diagnosis (A1/A2/A3) (n = 65) | 10/46/9 | |||
Location (L1/L2/L3/L4) (n = 65) | 10/24/31/0 | |||
Behavior (B1/B2/B3) (n = 65) | 38/19/8 | |||
Montreal classification UC | ||||
Disease extension (E1/E2/E3) (n = 107) | 34/47/26 | |||
